Affera combines mapping technology with a catheter capable of performing radiofrequency and pulsed field ablation.

This content was published on Oct 24, 2024 On Thursday, the Swiss Federal Railways presented its first fully renovated InterCity tilting train (ICN). Read more: Swiss railways presents first fully ...

Mizuho raised the firm’s price target on Boston Scientific (BSX) to $110 from $100 and keeps an Outperform rating on the shares post the ...

William Plovanic, an analyst from Canaccord Genuity, maintained the Buy rating on Boston Scientific (BSX – Research Report). The ...

Q3 2024 Earnings Call Transcript October 23, 2024 Boston Scientific Corporation beats earnings expectations. Reported EPS is ...

The med-tech company with approximately 9,400 employees in Minnesota posted profit and sales that beat Wall Street’s ...

In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and ...

Demand for the pulsed field ablation device drove the company’s electrophysiology sales up 177% in the third quarter compared ...

Despite a trial pause, Boston Scientific's impressive Q3 results and strategic expansions hint at a promising growth ...

Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third ...

Boston Scientific (BSX) shares fell 5% following news that the company has paused a study for its FARAPULSE PFA system due to ...